相关实验视频
Updated: Jan 9, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
877
通过对ALK+ NSCLC患者进行结构化运动干预来管理洛拉提尼布诱导的体重增加:一个病例报告
Christian Ciurnelli1, Ilaria Mariangela Scaglione2, Serena Eccher2
1Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Frontiers in oncology
|December 8, 2025
概括
运动干预可以帮助管理非小细胞肺癌 (NSCLC) 患者的体重增加,这些患者接受ALK氨酸激酶抑制剂 (TKIs) 治疗. 一个结构化的程序改善了身体组成和生活质量,这表明了未来研究的潜力.
科学领域:
- 在瘤学瘤学.
- 运动生理学 运动生理学
- 癌症康复 癌症康复
背景情况:
- 接受ALK氨酸激酶抑制剂 (TKIs) 治疗的非小细胞肺癌 (NSCLC) 患者经常会显著增加体重,主要是在脂肪组织中.
- 目前对TKI诱导的体重增加的管理策略有限,没有确立的非药物干预措施.
- 现有的研究缺乏关于炼干预措施对在NSCLC患者中管理这种特定副作用的有效性的数据.
研究的目的:
- 评估结构化炼计划对ALK重组NSCLC患者接受Lorlatinib治疗的体重增加管理的影响.
- 评估6个月的运动干预后身体组成,身体健康和患者报告的结果的变化.
主要方法:
- 一名43岁的男性转移性ALK重组NSCLC患者,体重增加1级,参加了为期6个月的炼计划.
- 该计划包括每周两次有氧 (连续和间歇) 和中等到剧烈强度的抵抗运动.
- 评估包括体能测试,患者报告的结果,生物阻抗和CT扫描用于身体组成分析.
主要成果:
- 体重保持稳定,但身体组成分析显示脂肪质量减少,肌肉质量增加.
- 患者报告说,心肺健康,肌肉强度,耐力和灵活性有显著改善.
- 患者报告的结果表明,生活质量的各个领域都得到了改善.
结论:
- 本案例报告表明,结构化炼干预可以积极影响与TKI相关的体重增加的NSCLC患者的身体组成和生活质量.
- 这些发现支持进一步进行干预研究的必要性,以确定运动在预防或控制患者群体体重增加方面的有效性.
相关概念视频
01:21Drug Dosing: Obese Patients
202
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
202
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
225
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
225
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161
01:22Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235